FMP
Nov 13, 2024 3:00 PM - Stuart Mooney(Last modified: Nov 14, 2024 10:01 AM)
Image credit: Google Images
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative treatments, including AXS-07 for migraines and AXS-05 for Alzheimer's agitation. Despite its promising pipeline, Axsome faces competition from major pharmaceutical companies, which adds pressure to its financial performance.
On November 12, 2024, Axsome reported its Q3 earnings, revealing an EPS of -$1.34, which was better than the estimated -$1.38. This marks a slight increase from the -$1.32 EPS reported in the same quarter last year. The company achieved an earnings surprise of 2.90%, continuing its trend of surpassing consensus EPS estimates over the past four quarters.
Axsome's revenue for the quarter was approximately $104.8 million, surpassing the estimated $98.1 million and marking an 81% year-over-year growth. This performance exceeded the Zacks Consensus Estimate by 6.13%. The company has consistently outperformed consensus revenue estimates in each of the last four quarters, reflecting strong sales growth.
Despite these positive results, Axsome's path to profitability remains challenging. The company reported a net loss of $64.6 million for the quarter, highlighting substantial cash burn. Axsome's negative P/E ratio of -16.16 and negative earnings yield of -6.19% indicate ongoing profitability challenges. The enterprise value to operating cash flow ratio is also negative at -36.77, underscoring difficulties in generating positive cash flow.
Axsome's financial health is further illustrated by its debt-to-equity ratio of 2.06, indicating significant reliance on debt financing. However, the company maintains a strong current ratio of 2.44, suggesting it can cover short-term liabilities with its short-term assets. As Axsome anticipates FDA approval for AXS-07 in January, the potential for these treatments to achieve significant revenue remains uncertain.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...